Aesculap: Strategic Analysis of Leading Orthopedics Companies

A strategic assessment of Aesculap, one of the world' s leading orthopedics companies, provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs. The report presents a comprehensive analysis of the company 's performance, capabilities, goals and strategies in the global orthopedics market.

Executive Summary Business Organization Senior Management Facilities and Employees Technological Know-how Product Portfolio Marketing Tactics Sales and Profit Growth R&D Expenditures and Major Programs Collaborative Arrangements Strategic Direction List of Tables Aesculap Sales and Operating Profit Growth Aesculap Sales by Division Aesculap Sales Growth by Division Aesculap Sales by Geographic Region Aesculap Sales Growth by Geographic Region

For more information kindly visit : Aesculap: Strategic Analysis of Leading Orthopedics Companies

DiaPat GmbH - Product Pipeline Analysis

Diapat Gmbh (Diapat) is a diagnosis services provider. The company provides diagnosis of various diseases such as coronary artery disease, diabetic nephropathy, bladder cancer, chronic nephropathies, heart failure and vesicoureteral reflux. It specilaizes in the reliable detection of diseases at early stages and evaluation of therapy, enabling personalized medicine. The company's DiaPat technology based on the innovative coupling of capillary electrophoresis and mass spectrometry identifies up to 6,000 of the proteins and polypeptides. It conducts research and development activities in partnership with universities and institutes including Harvard University, Beatson Institute, NHFML University of Florida and Austin Health. Diapat is headquartered in Hannover, Germany.

This report is a source for data, analysis and actionable intelligence on the DiaPat GmbH portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date

Each pipeline product is profiled to cover information on product description, function, technology, indication, and application. The report is also supplemented with a detailed company profile and information on clinical trials, wherever applicable.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

- Detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments.
- Detailed coverage on all the pipeline products, by equipment type, by therapy area, by development stage, and by trial phase.
- Information on product milestones and pipeline territory for each product, the estimated approval date, and estimated launch date.
- Profile of each pipeline product with additional information on product description, function, technology, indication(s), and application.
- Data on relevant clinical trials and product patent details, wherever applicable.

For more information visit : DiaPat GmbH - Product Pipeline Analysis

Aragon Pharmaceuticals, Inc. - Product Pipeline Review - 2012

Aragon Pharmaceuticals, Inc. - Product Pipeline Review - 2012” provides data on the Aragon Pharmaceuticals, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Aragon Pharmaceuticals, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Aragon Pharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team. Scope - Aragon Pharmaceuticals, Inc. - Brief Aragon Pharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries. - Review of current pipeline of Aragon Pharmaceuticals, Inc. human therapeutic division. - Overview of pipeline therapeutics across various therapy areas. - Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe. and Swot Analysis - Product profiles for late stage and clinical stage products of Aragon Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones. - Recent updates of the Aragon Pharmaceuticals, Inc.’s pipeline in the last quarter. - Key discontinued and dormant projects. - Latest news and deals relating to the products. Reasons to buy - Evaluate Aragon Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline. - Assess the growth potential of Aragon Pharmaceuticals, Inc. in its therapy areas of focus. - Identify new drug targets and therapeutic classes in the Aragon Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas. - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps. - Exploit collaboration and partnership opportunities with Aragon Pharmaceuticals, Inc.. - Avoid Intellectual Property Rights related issues. - Explore the dormant and discontinued projects of Aragon Pharmaceuticals, Inc. and identify potential opportunities in those areas. For more information on Aragon Pharmaceuticals, Inc.

Alafair Biosciences, Inc. - Product Pipeline Analysis

Alafair Biosciences, Inc.( Alafair) is a medical equipment company. It develops cross-linked polysaccharide hydrogel films to address the post-surgical complication of unwanted soft tissue attachments or tethering between opposing tissue surface. Alafair’s initial product is a film that shows superior handling and mechanical properties. Its follow-on product pipeline includes membrane, bilayer, and injectable gel solutions for applications in scar prevention, wound care, and tissue reconstruction. The company has a sponsored research agreement with the university of Texas and has acquired world-wide exclusive rights to the hydrogel platform technology from the university for all fields of use. The company is headquartered at Austin, Texas, the US.

This report is a source for data, analysis and actionable intelligence on the Alafair Biosciences, Inc. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date

Each pipeline product is profiled to cover information on product description, function, technology, indication, and application. The report is also supplemented with a detailed company profile and information on clinical trials, wherever applicable.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by industry experts.

Scope

- Detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments.
- Detailed coverage on all the pipeline products, by equipment type, by therapy area, by development stage, and by trial phase.
- Information on product milestones and pipeline territory for each product, the estimated approval date, and estimated launch date.
- Profile of each pipeline product with additional information on product description, function, technology, indication(s), and application.
- Data on relevant clinical trials and product patent details, wherever applicable.
- Information on clinical trial, wherever applicable, is supplemented with information on trial phase, trial status, trial objective, trial design, target patients, unique physician identifier, primary point, secondary point, acronym, participants inclusion, participants exclusion, interventions, trial results, trial start date, trial end date, study type, trial site, trial funding, age eligibility, and gender eligibility.

For more information on Alafair Biosciences, Inc.